Tags

Type your tag names separated by a space and hit enter

Effects of pranlukast, a cysteinyl leukotriene antagonist, on bronchial responsiveness to methacholine in aspirin-intolerant asthmatics treated with corticosteroids.
Hiroshima J Med Sci. 2000 Jun; 49(2):105-8.HJ

Abstract

Cysteinyl leukotrienes (cysLTs) are considered to be the most important mediator involved in the pathogenesis of aspirin-intolerant asthma (AIA). However, the role of cysLTs in the baseline condition of the pathophysiology of AIA when not exposed to non-steroidal antiinflammatory drugs (NSAIDs) as well as that in the pathophysiology of aspirin-tolerant asthma remains to be elucidated. Therefore, we evaluated the effect of pranlukast, a potent, selective cysLT receptor antagonist, on bronchial responsiveness to methacholine, a non-specific stimulus, in 7 well-controlled aspirin-intolerant asthmatics receiving oral or inhaled corticosteroid treatment. Pranlukast was orally administered at a dose of 225 mg twice daily to all patients for 4 weeks, and the methacholine challenge test was performed before and after pranlukast treatment. The methacholine provocative concentration producing a 20% fall in forced expiratory volume in 1 second (PC20-FEV1) was calculated as an index of bronchial hyperresponsiveness (BHR). The geometric mean values of PC20-FEV1 significantly (p = 0.028) increased from 0.34 mg/dl to 0.61 mg/dl after pranlukast treatment. No significant differences were observed in the baseline values of forced vital capacity (FVC) or FEV1 before and after pranlukast treatment. These findings suggest that antagonism of endogenous cysLT by pranlukast may be responsible for the improvement of BHR to methacholine.

Authors+Show Affiliations

Second Department of Internal Medicine, Hiroshima University School of Medicine, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10920576

Citation

Ishioka, S, et al. "Effects of Pranlukast, a Cysteinyl Leukotriene Antagonist, On Bronchial Responsiveness to Methacholine in Aspirin-intolerant Asthmatics Treated With Corticosteroids." Hiroshima Journal of Medical Sciences, vol. 49, no. 2, 2000, pp. 105-8.
Ishioka S, Hozawa S, Haruta Y, et al. Effects of pranlukast, a cysteinyl leukotriene antagonist, on bronchial responsiveness to methacholine in aspirin-intolerant asthmatics treated with corticosteroids. Hiroshima J Med Sci. 2000;49(2):105-8.
Ishioka, S., Hozawa, S., Haruta, Y., Maeda, A., Tamagawa, K., Watanabe, T., Hiyama, K., & Yamakido, M. (2000). Effects of pranlukast, a cysteinyl leukotriene antagonist, on bronchial responsiveness to methacholine in aspirin-intolerant asthmatics treated with corticosteroids. Hiroshima Journal of Medical Sciences, 49(2), 105-8.
Ishioka S, et al. Effects of Pranlukast, a Cysteinyl Leukotriene Antagonist, On Bronchial Responsiveness to Methacholine in Aspirin-intolerant Asthmatics Treated With Corticosteroids. Hiroshima J Med Sci. 2000;49(2):105-8. PubMed PMID: 10920576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of pranlukast, a cysteinyl leukotriene antagonist, on bronchial responsiveness to methacholine in aspirin-intolerant asthmatics treated with corticosteroids. AU - Ishioka,S, AU - Hozawa,S, AU - Haruta,Y, AU - Maeda,A, AU - Tamagawa,K, AU - Watanabe,T, AU - Hiyama,K, AU - Yamakido,M, PY - 2000/8/2/pubmed PY - 2000/9/2/medline PY - 2000/8/2/entrez SP - 105 EP - 8 JF - Hiroshima journal of medical sciences JO - Hiroshima J. Med. Sci. VL - 49 IS - 2 N2 - Cysteinyl leukotrienes (cysLTs) are considered to be the most important mediator involved in the pathogenesis of aspirin-intolerant asthma (AIA). However, the role of cysLTs in the baseline condition of the pathophysiology of AIA when not exposed to non-steroidal antiinflammatory drugs (NSAIDs) as well as that in the pathophysiology of aspirin-tolerant asthma remains to be elucidated. Therefore, we evaluated the effect of pranlukast, a potent, selective cysLT receptor antagonist, on bronchial responsiveness to methacholine, a non-specific stimulus, in 7 well-controlled aspirin-intolerant asthmatics receiving oral or inhaled corticosteroid treatment. Pranlukast was orally administered at a dose of 225 mg twice daily to all patients for 4 weeks, and the methacholine challenge test was performed before and after pranlukast treatment. The methacholine provocative concentration producing a 20% fall in forced expiratory volume in 1 second (PC20-FEV1) was calculated as an index of bronchial hyperresponsiveness (BHR). The geometric mean values of PC20-FEV1 significantly (p = 0.028) increased from 0.34 mg/dl to 0.61 mg/dl after pranlukast treatment. No significant differences were observed in the baseline values of forced vital capacity (FVC) or FEV1 before and after pranlukast treatment. These findings suggest that antagonism of endogenous cysLT by pranlukast may be responsible for the improvement of BHR to methacholine. SN - 0018-2052 UR - https://www.unboundmedicine.com/medline/citation/10920576/Effects_of_pranlukast_a_cysteinyl_leukotriene_antagonist_on_bronchial_responsiveness_to_methacholine_in_aspirin_intolerant_asthmatics_treated_with_corticosteroids_ L2 - https://medlineplus.gov/asthma.html DB - PRIME DP - Unbound Medicine ER -